2024 World Conference on Lung Cancer (WCLC) - Posters-P2.04A.08 Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

Pdf Summary

The study titled "Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer: Trial in Progress" explores the utility of a DELFI cell-free DNA (cfDNA) liquid biopsy as an alternative to Low-Dose Computed Tomography (LDCT) for lung cancer screening (LCS). There is a noted underutilization of LDCT, especially among underserved populations, due to various complex barriers. The innovative DELFI cfDNA liquid biopsy, which can be done at home, aims to address these barriers by increasing the accessibility and participation rates in lung cancer screening.<br /><br />The study targets high-risk individuals aged 50-80 with a smoking history of 20 pack-years who have quit in the past 15 years. Participants are recruited in both urban and rural settings, with options to undergo either a liquid biopsy (Cohort A) or LDCT (Cohort B), followed by surveys to track acceptability and efficacy over six months.<br /><br />Key objectives include determining the proportion of participants opting for liquid biopsy, assessing the feasibility of home testing, and examining the socio-demographic factors affecting choice and compliance. The primary goal is to have at least 30% of participants preferring the blood test over traditional screening methods.<br /><br />The trial, supported by the American Cancer Society, began enrolment on March 25, 2024, and aims to complete primary data collection by December 31, 2025. With a target of 100 participants from federally qualified health centers, mobile screening units, and rural programs, the study will provide insights into the feasibility of liquid biopsies in LCS, potentially paving the way for broader clinical trials focused on early detection of lung cancer in resource-strapped areas.

Asset Subtitle

Loretta Erhunmwunsee

Meta Tag

Speaker Loretta Erhunmwunsee

Topic Screening & Early Detection

Keywords

cell-free DNA

liquid biopsy

lung cancer screening

DELFI cfDNA

low-dose computed tomography

high-risk patients

smoking history

home testing

socio-demographic factors

American Cancer Society